Clinical Trials on Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Total 107 results
-
Celgene CorporationCompletedLow- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)United States
-
Forma Therapeutics, Inc.RecruitingVery Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-RUnited States, France, Canada, Germany
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedMyelodysplastic Syndrome | MDS | Low to Intermediate-1 MDS | Non-deletion 5qUnited States
-
FibroGenAstraZeneca; Astellas Pharma IncTerminatedPrimary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMyelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | IPSS Risk Category Intermediate-1United States
-
Peking Union Medical College HospitalUnknownLow/Intermediate Risk-1 MDSChina
-
Merck Sharp & Dohme LLCCompletedMyelodysplastic Syndromes | Anemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Low to Intermediate-1 MDSUnited States, France
-
Novartis PharmaceuticalsCompletedLow and Int 1-risk Myelodysplastic SyndromeGermany, Canada, Korea, Republic of, Sweden, Spain, China, Argentina, Italy, United Kingdom, Algeria
-
Assistance Publique - Hôpitaux de ParisUnknownInfection | Risk Factors | Myelodysplastic Syndrome (MDS) | IPSS High RiskFrance
-
GWT-TUD GmbHAmsterdam UMC, location VUmc; BerGenBio ASA; Groupe Francophone des MyelodysplasiesCompletedAcute Myeloid Leukemia | High-risk Myelodysplastic Syndrome | Low-risk Myelodysplastic SyndromeGermany, Netherlands, France
-
Novartis PharmaceuticalsTerminated
-
Silence Therapeutics plcCompletedNon-transfusion-dependent Thalassemia | Low Risk Myelodysplastic Syndrome | Very-Low Risk Myelodysplastic SyndromeThailand, Israel, Jordan, United Kingdom, Germany, Italy, Malaysia
-
Novartis PharmaceuticalsActive, not recruitingAcute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)Spain, Singapore, Australia, Germany, Italy, Finland, United States
-
University of UlmTerminatedAcute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)Germany
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Institut fuer anwendungsorientierte Forschung und...University Medical Center GoettingenCompletedMyelodysplastic Syndromes (MDS) | Chromosmal Aberrations | Karyotype Evolution | Rare Abnormalities | Cytogenetic MonitoringGermany
-
Rigel PharmaceuticalsRecruitingLow Risk Myelodysplastic SyndromesUnited States
-
Institute of Hematology & Blood Diseases Hospital...Beijing Health Alliance Charitable FoundationRecruitingLower Risk MDS Per IPSS-RChina
-
Abramson Cancer Center of the University of PennsylvaniaCompletedHigh Risk MDS or AML PatientsUnited States
-
Ginna LaportTerminatedAcute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors | Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase | Myelodysplastic Syndrome (MDS) - High and Intermediate Risk | Non-Hodgkin's Lymphoma (NHL) | Chronic Lymphocytic Leukemia...United States
-
University of UlmRecruitingAcute Myeloid Leukemia (AML) | Higher Risk Myelodysplastic Syndromes (MDS With Excess Blasts 2)Austria, Germany
-
Silence Therapeutics plcWithdrawnNon-transfusion-dependent Thalassemia | Low Risk Myelodysplastic SyndromeUnited Kingdom, Bulgaria
-
Ascentage Pharma Group Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML | High-risk Myelodysplastic SyndromeUnited States
-
Cell Medica LtdUniversity College, London; Cell Therapy CatapultCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)United Kingdom, Germany, Belgium
-
Opna-IO LLCCompletedHigh-risk Myelodysplastic Syndrome (MDS) | Relapsed Acute Myeloid Leukemia (AML) | Refractory Acute Myeloid Leukemia (AML)United States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyelodysplastic Syndrome (MDS)United States
-
Novartis PharmaceuticalsCompletedAML and High Risk MDSGermany, Italy, France, Netherlands, United States, Australia, Japan
-
Henry Ford Health SystemAmerican Cancer Society, Inc.WithdrawnLow or Intermediate Risk Prostate CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Acute Myeloid Leukemia With Multilineage Dysplasia | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Blasts 20-30 Percent of Peripheral Blood White Cells | IPSS Risk Category Intermediate-2United States
-
CelgeneRecruitingBeta-thalassemia | Myelodysplastic Syndromes (MDS) | Myeloproliferative Neoplasm(MPN)-Associated MyelofibrosisUnited States, Japan, Israel, United Kingdom, Turkey, Greece, France, Australia, Belgium, Bulgaria, Canada, Germany, Italy, Malaysia, Spain, Sweden, Taiwan, Thailand, Tunisia, China, Lebanon, Netherlands
-
Singapore General HospitalShanghai Yueyang Integrated Medicine Hospital; Singapore Bao Zhong Tang TCM...CompletedMyelodysplastic Syndrome (MDS) | Myelofibrosis (MF) | Thalassemia Intermedia | Aplastic Anaemia (AA)Singapore
-
Jason Robert GotlibCelgene CorporationTerminatedLeukemia | Anemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Recurrent Acute Biphenotypic Leukemia | Blasts 20 Percent or More of Bone Marrow Nucleated Cells | Recurrent High Risk Myelodysplastic Syndrome | Refractory High Risk...United States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...TerminatedHodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Acute Leukemia | Hematologic Malignancies | Myeloma | Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes | Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI TherapyUnited States
-
Everett MeyerCompletedLeukemia, Myeloid | Myeloproliferative Disorders | Anemia | Neural Tube Defects | Myelodysplastic Syndromes (MDS) | Bone Marrow Transplant FailureUnited States
-
Genesis Research LLCRecruitingProstate Cancer | Low-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance RegimenUnited States
-
Karyopharm Therapeutics IncActive, not recruitingAcute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDSUnited States, France, Canada, Spain, China
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaActive, not recruitingLow or Intermediate Risk Prostate CancerCanada
-
Dana-Farber Cancer InstituteActive, not recruitingRecurrent, Refractory, or High Risk Leukemias | Matched Targeted TherapyUnited States
-
NexImmune Inc.Active, not recruitingAcute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)United States
-
Franziska WachterHarvard Clinical and Translational Science Center (Harvard Catalyst)RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | MDS | Aml | Myeloid Neoplasm | Myeloid Malignancies | Inherited Bone Marrow Failure SyndromeUnited States
-
Roswell Park Cancer InstituteCelldex TherapeuticsCompletedAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Refractory Anemia | Blasts 30 Percent or Less of Bone Marrow Nucleated CellsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedAcute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Chronic Myeloid Leukemia (CML)United States
-
Mayo ClinicRecruitingHematologic Neoplasms | Myeloid Malignancy | Cytopenia | Bone Marrow Failure Syndrome | Clonal Cytopenia of Undetermined Significance | Clonal Hematopoiesis of Indeterminate Potential | Low Risk Myelodysplastic Syndrome | Inherited Bone Marrow Failure Syndrome | Clonal Expansion | Hereditary Neoplastic... and other conditionsUnited States
-
Rennes University HospitalNot yet recruitingHysterectomies for Low- or Intermediate-risk Endometrial CarcinomaFrance
-
Alaunos TherapeuticsCompletedLymphoma | Multiple Myeloma | Acute Leukemia | Chronic Myeloproliferative Disease | Chronic Lymphoproliferative Disease | Poor-risk Myelodysplasia (MDS)United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia | High Risk... and other conditionsUnited States
-
Boston Children's HospitalCompletedAML | ALL | Biphenotypic Leukemia | Refractory Anemia | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Ringed Sideroblasts | Undifferentiated Leukemia | Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts | Refractory Anemia With Excess Blasts-1 (5-10% Blasts) | Refractory... and other conditionsUnited States
-
Ultragenyx Pharmaceutical IncAvailableGlucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
-
Ultragenyx Pharmaceutical IncCompletedGlucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)United States, Spain, Australia, France, Israel, Italy, United Kingdom